论文部分内容阅读
目的:分析米非司酮联合桂枝茯苓丸治疗子宫内膜异位症的临床效果。方法:106例子宫内膜异位症患者按抽签法分为对照组(n=53)与实验组(n=53),对照组采用米非司酮治疗,实验组基于对照组加以桂枝茯苓丸治疗,比较两组的临床疗效,治疗前后血清癌抗原125(CA125)、癌抗原199(CA199)、血管内皮生长因子(VEGF)、超氧化物歧化酶(SOD),白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)、血浆黏度、全血黏度、红细胞聚集指数的变化。结果:实验组的治疗总有效率为94.33%,显著高于对照组,差异有统计学意义(P<0.05)。实验组治疗后血清CA125、CA199、VEGF、SOD、IL-6、IL-8、TNF-α、hs-CRP水平、血浆黏度、全血黏度、红细胞聚集指数均明显低于对照组(P<0.05)。结论:米非司酮联合桂枝茯苓丸治疗子宫内膜异位症的临床疗效确切,可能与其抗炎、抗氧化和改善血液流变学作用有关。
Objective: To analyze the clinical effect of mifepristone and Guizhi Fuling capsule in the treatment of endometriosis. Methods: One hundred and sixty patients with endometriosis were randomly divided into control group (n = 53) and experimental group (n = 53) by lottery. The control group was treated with mifepristone. The experimental group was treated with Guizhi Fuling The clinical efficacy of the two groups were compared before and after treatment. The levels of serum CA125, CA199, VEGF, SOD and IL - IL-6, IL-8, TNF-α, hs-CRP, plasma viscosity, whole blood viscosity and erythrocyte aggregation index . Results: The total effective rate of the experimental group was 94.33%, which was significantly higher than that of the control group (P <0.05). The levels of serum CA125, CA199, VEGF, SOD, IL-6, IL-8, TNF-α and hs-CRP, plasma viscosity, whole blood viscosity and erythrocyte aggregation index in the experimental group were significantly lower than those in the control group ). Conclusion: The clinical efficacy of mifepristone combined with Guizhi Fuling capsule in the treatment of endometriosis may be related to its anti-inflammatory, anti-oxidation and hemorrheological effects.